Top 10 Innovations: EMD Millipore’s CellASIC™ Platform Takes 6th Place with
Live Cell Imaging and Precise Environment Control
*The Scientist magazine placed EMD Millipore’s CellASIC™ ONIX Microfluidic
Platform in 6th place in its annual Top 10 Innovations contest
*Platform uses microfluidic perfusion to mimic the in vivo cell environment
for more predictive cell analysis
*Dynamic, automated control of gas, temperature and flow enables
uninterrupted live cell imaging
BILLERICA, Mass. -- December 03, 2012
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany,
today announced that its CellASIC™ ONIX Microfluidic Platform was ranked 6th
among the top ten innovations of 2012 as determined by a panel of expert
judges at The Scientist magazine.
“We’re honored that The Scientist has recognized the CellASIC™ platform as a
game-changing technology, potentially enabling more predictive cell analysis,”
said Philip Lee, Ph.D., co-founder of CellASIC Corporation (now part of EMD
Millipore). “We look forward to working with our customers to make
microfluidic cell culture the standard in research and drug discovery.”
Already adopted by laboratories around the world, CellASIC™ technology has
given cell biologists unprecedented abilities to monitor responses to
pre-programmed perfusion, temperature and gas environment changes in live
cells. Using microfluidic perfusion to mimic in vivo environments, the
CellASIC™ ONIX Platform automates all the necessary requirements for live cell
imaging while maintaining optimal health of cells, even over several days.
The platform, which consists of a control system, microfluidic plates and
software, is compatible with standard inverted microscopes.
Application-specific microfluidic plates support mammalian, yeast or bacterial
cells. Applications greatly facilitated by CellASIC™ technology include: 3D
cell culture, dynamic primary neuron culture, cancer response to hypoxia, and
About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers
a broad range of innovative, performance products, services and business
relationships that enable our customers' success in research, development and
production of biotech and pharmaceutical drug therapies. Through dedicated
collaboration on new scientific and engineering insights, and as one of the
top three R&D investors in the Life Science Tools industry, EMD Millipore
serves as a strategic partner to customers and helps advance the promise of
Headquartered in Billerica, Massachusetts, the division has around 10,000
employees, operations in 67 countries and 2010 revenues of $2.2 billion. EMD
Millipore is known as Merck Millipore outside of the U.S. and Canada.
Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany
All Merck Press Releases are distributed by e-mail at the same time they
become available on the Merck Website. Please go to
http://www.merck.de/subscribe to register online, change your selection or
discontinue this service.
Merck is a global pharmaceutical and chemical company with total revenues of €
10.3 billion in 2011, a history that began in 1668, and a future shaped by
more than 40,000 employees in 67 countries. Its success is characterized by
innovations from entrepreneurial employees. Merck's operating activities come
under the umbrella of Merck KGaA, in which the Merck family holds an
approximately 70% interest and shareholders own the remaining approximately
30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an
independent company ever since.
Geoffrey Schwartz, +1 951 514 4223
Press spacebar to pause and continue. Press esc to stop.